Abstracts tagged "MAS"

Abstract Number: 099 • 2020 Pediatric Rheumatology Symposium
Reversible Hepatotoxicity to IL-1/IL-6 Blockade in Pediatric Patients with Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome
Omkar Phadke¹, Sampath Prahalad ² and Kelly Rouster-Stevens ³, ¹EMORY, Atlanta, Georgia, ²Emory + Children's Pediatric Institute, Atlanta, ³Emory University/Children's Healthcare of Atlanta, Atlanta, Georgia
Background/Purpose: Treatment for systemic JIA (sJIA) complicated by macrophage activation syndrome (MAS) may involve blockade of IL-1 and IL-6. There are reports of adults with…
Abstract Number: 152 • 2020 Pediatric Rheumatology Symposium
Hemophagocytic Lymphohistiocytosis (HLH) Genetic Variants in Childhood-onset SLE (cSLE) with Macrophage Activation Syndrome (MAS)
Piya Lahiry¹, Sergey Naumenko ², Fangming Liao ³, Daniela Dominguez ⁴, Andrea Knight ⁵, Deborah Levy ³, Lawrence Ng ⁴, Earl D. Silverman ⁶ and Linda Hiraki ⁷, ¹Hospital for Sick Children, Toronto, Canada, ²The Centre for Computational Medicine, Toronto, Canada, ³Division of Rheumatology, The Hospital for Sick Children, Department of Pediatrics, University of Toronto, Toronto, Canada, ⁴Division of Rheumatology, The Hospital for Sick Children, Toronto, Canada, ⁵SickKids Research Institute, Toronto, Canada, ⁶Division of Rheumatology, The Hospital for Sick Children, Department of Paediatrics, University of Toronto, Translational Medicine, Research Institute, The Hospital for Sick Children, Toronto, Canada, ⁷Division of Rheumatology, The Hospital for Sick Children, Department of Paediatrics, University of Toronto, Child Health Evaluative Sciences, Research Institute, The Hospital for Sick Children, Toronto, Canada
Background/Purpose: Hemophagocytic lymphohistocytosis (HLH) is a life-threatening hyper-inflammatory syndrome characterized by excessive activation and proliferation of T-lymphocytes and macrophages. Familial HLH (fHLH), is an autosomal…
Abstract Number: 010 • 2020 Pediatric Rheumatology Symposium
Experience with and Management of HLH-like Toxicities Following Chimeric Antigen Receptor T-Cell Therapy for Treatment of Relapsed/Refractory Pre-B ALL
Amanda Ombrello¹, Bonnie Yates ², Haneen Shalabi ², Terry Fry ³ and Nirali Shah ², ¹National Human Genome Research Institute/National Institutes of Health, Bethesda, ²National Cancer Institute/National Institutes of Health, Bethesda, ³University of Colorado, Denver/Children's Hospital Colorado, Denver
Background/Purpose: Chimeric antigen receptor T-cell (CAR-T) therapy is a highly effective form of adoptive cell immunotherapy combining antigen specific targeting capabilities with T-cell based cytotoxicity.…
Abstract Number: 076 • 2020 Pediatric Rheumatology Symposium
How Do Pediatric Rheumatologists Diagnose Macrophage Activation Syndrome in Systemic Onset Juvenile Idiopathic Arthritis? An Examination of the CARRA Registry
Taha Moussa¹, Moussa Abdelhak ² and Cuoghi Edens ³ for the CARRA investigators, ¹University of Chicago Medicine, Chicago, ²Cambridge GPVTS, Cambridge, United Kingdom, ³University of Chicago, Chicago
Background/Purpose: Macrophage activation syndrome (MAS) is a feared complication in~ 10% of those systemic onset juvenile idiopathic arthritis (sJIA). Due to the similarity of MAS…
Abstract Number: 920 • 2019 ACR/ARP Annual Meeting
Adenosine Deaminase 2 as a Circulating Biomarker of Macrophage Activation Syndrome
Pui Lee¹, Grant Schulert ², Scott Canna ³, Yuelong Huang ⁴, Jacob Sundel ⁴, Mary Beth Son ¹, Lauren Henderson ¹, Peter Nigrovic ⁵, Jane Newburger ⁶, Fatma Dedeoglu ⁶, Mindy Lo ⁶, Esra Meidan ⁶, Ying Li ⁴, Olha Halyabar ⁶, Margaret Chang ⁷, Kacie Hoyt ⁶, Thuy Do ², Robert Sundel ⁸ and Rachel Blaustein ⁴, ¹Boston Children's Hospital, Boston, MA, ²Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³UPMC Children's Hospital of Pittsburgh, Pittsburgh, ⁴Brigham and Women's Hospital, Boston, ⁵Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA ; Department of Medicine, Division of Immunology, Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA., Boston, ⁶Boston Children's Hospital, Boston, ⁷Division of Immunology, Boston Children's Hospital, Boston, ⁸Boston Children’s Hospital, Harvard Medical School, Boston
Background/Purpose: Macrophage activation syndrome (MAS) is a life-threatening complication of systemic juvenile idiopathic arthritis (sJIA) characterized by a vicious cycle of immune cell activation and…
Abstract Number: 938 • 2017 ACR/ARHP Annual Meeting
A Germline Macrophage Activation Syndrome-Associated Nlrc4 Mutation Causes Chronic, Systemic, Non-Hematopoietic IL-18 Elevation and Intestinal MHC-II Upregulation
Eric Weiss¹, Corinne Schneider² and Scott Canna³, ¹RK Mellon Institute, Children’s Hospital of Pittsburgh, Pittsburgh, PA, ²Pediatrics, Children's Hospital Pittsburgh, Pittsburgh, PA, ³NIAMS, National Institutes of Health, Bethesda, MD
Background/Purpose: Patients prone to the development of Macrophage Activation Syndrome (MAS) can have extreme and often chronic elevation in the pro-inflammatory cytokine interleukin-18 (IL-18). In…
Abstract Number: 1597 • 2017 ACR/ARHP Annual Meeting
Arthritis and Hydroxychloroquine Are Associated with Decreased Risk of Macrophage Activation Syndrome Among Adults Hospitalized with SLE
Kristin D'Silva¹, Ezra Cohen², David J. Kreps³, Mary Beth Son² and Karen H. Costenbader³, ¹Internal Medicine, Brigham and Women's Hospital, Boston, MA, ²Boston Children's Hospital, Boston, MA, ³Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Macrophage activation syndrome (MAS) is an uncommon but potentially fatal complication of SLE. We conducted a case-control study comparing hospitalized adults with SLE with…
Abstract Number: 1401 • 2015 ACR/ARHP Annual Meeting
Is There Any Difference Between Autoimmune or Hemato-Oncology Etiology of Macrophage Activation Syndrome?
César Antonio Egües Dubuc, Miren Uriarte Ecenarro, Nerea Errazquin Aguirre, Olga Maiz Alonso, Iñaki Hernando Rubio and Joaquin Maria Belzunegui Otano, Rheumatology, Donostia University Hospital, Donostia, Spain
Background/Purpose: Macrophage activation syndrome (MAS) is a group of diseases, especially autoimmune (AI) and hemato-oncology (HO). So it will be interesting to find any clinical…
Abstract Number: 1312 • 2014 ACR/ARHP Annual Meeting
Features, Treatment and Outcome of Macrophage Activation Syndrome in Pediatric Systemic Lupus Erythematosus
Roberto Ezequiel Borgia¹, Maya Gerstein¹, Deborah M. Levy², Earl D. Silverman¹ and Linda T Hiraki³, ¹Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ²Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ³The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Macrophage activation syndrome (MAS) is a life-threatening inflammatory complication of pediatric systemic lupus erythematosus (pSLE). There are few reports of the presentation, treatment and outcome of…
Abstract Number: 310 • 2014 ACR/ARHP Annual Meeting
Differential Expression of microRNA in Monocytes from Children with Systemic Juvenile Idiopathic Arthritis: Implications for Polarized Phenotype
Grant Schulert¹, Ndate Fall², Nan Shen³ and Alexei Grom⁴, ¹Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Rheumatology, Shanghai Institutes for Biological Sciences Chinese Academy of Sciences & Shanghai Jiao Tong University School of Medicine, Shanghai, OH, China, ⁴Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Systemic juvenile idiopathic arthritis (SJIA) is an autoinflammatory disease of childhood, and the predominant effector cells are mononuclear phagocytes rather than lymphocytes as in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].